101 related articles for article (PubMed ID: 34981073)
1. COVID-19 vaccination effectiveness rates by week and sources of bias.
Ostropolets A; Hripcsak G
medRxiv; 2021 Dec; ():. PubMed ID: 34981073
[TBL] [Abstract][Full Text] [Related]
2. COVID-19 vaccination effectiveness rates by week and sources of bias: a retrospective cohort study.
Ostropolets A; Hripcsak G
BMJ Open; 2022 Aug; 12(8):e061126. PubMed ID: 35998962
[TBL] [Abstract][Full Text] [Related]
3. Comparative Effectiveness and Antibody Responses to Moderna and Pfizer-BioNTech COVID-19 Vaccines among Hospitalized Veterans - Five Veterans Affairs Medical Centers, United States, February 1-September 30, 2021.
Bajema KL; Dahl RM; Evener SL; Prill MM; Rodriguez-Barradas MC; Marconi VC; Beenhouwer DO; Holodniy M; Lucero-Obusan C; Brown ST; Tremarelli M; Epperson M; Mills L; Park SH; Rivera-Dominguez G; Morones RG; Ahmadi-Izadi G; Deovic R; Mendoza C; Jeong C; Schrag SJ; Meites E; Hall AJ; Kobayashi M; McMorrow M; Verani JR; Thornburg NJ; Surie D; ; ;
MMWR Morb Mortal Wkly Rep; 2021 Dec; 70(49):1700-1705. PubMed ID: 34882654
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness of Pfizer-BioNTech and Moderna Vaccines in Preventing SARS-CoV-2 Infection Among Nursing Home Residents Before and During Widespread Circulation of the SARS-CoV-2 B.1.617.2 (Delta) Variant - National Healthcare Safety Network, March 1-August 1, 2021.
Nanduri S; Pilishvili T; Derado G; Soe MM; Dollard P; Wu H; Li Q; Bagchi S; Dubendris H; Link-Gelles R; Jernigan JA; Budnitz D; Bell J; Benin A; Shang N; Edwards JR; Verani JR; Schrag SJ
MMWR Morb Mortal Wkly Rep; 2021 Aug; 70(34):1163-1166. PubMed ID: 34437519
[TBL] [Abstract][Full Text] [Related]
5. Use of COVID-19 Vaccines After Reports of Adverse Events Among Adult Recipients of Janssen (Johnson & Johnson) and mRNA COVID-19 Vaccines (Pfizer-BioNTech and Moderna): Update from the Advisory Committee on Immunization Practices - United States, July 2021.
Rosenblum HG; Hadler SC; Moulia D; Shimabukuro TT; Su JR; Tepper NK; Ess KC; Woo EJ; Mba-Jonas A; Alimchandani M; Nair N; Klein NP; Hanson KE; Markowitz LE; Wharton M; McNally VV; Romero JR; Talbot HK; Lee GM; Daley MF; Mbaeyi SA; Oliver SE
MMWR Morb Mortal Wkly Rep; 2021 Aug; 70(32):1094-1099. PubMed ID: 34383735
[TBL] [Abstract][Full Text] [Related]
6. Analysis of COVID-19 Incidence and Severity Among Adults Vaccinated With 2-Dose mRNA COVID-19 or Inactivated SARS-CoV-2 Vaccines With and Without Boosters in Singapore.
Ng OT; Marimuthu K; Lim N; Lim ZQ; Thevasagayam NM; Koh V; Chiew CJ; Ma S; Koh M; Low PY; Tan SB; Ho J; Maurer-Stroh S; Lee VJM; Leo YS; Tan KB; Cook AR; Tan CC
JAMA Netw Open; 2022 Aug; 5(8):e2228900. PubMed ID: 36018588
[TBL] [Abstract][Full Text] [Related]
7. The Effectiveness of Pfizer-BioNTech and Oxford-AstraZeneca Vaccines to Prevent Severe COVID-19 in Costa Rica: Nationwide, Ecological Study of Hospitalization Prevalence.
Rosero-Bixby L
JMIR Public Health Surveill; 2022 May; 8(5):e35054. PubMed ID: 35483079
[TBL] [Abstract][Full Text] [Related]
8. Association Between Vaccination With BNT162b2 and Incidence of Symptomatic and Asymptomatic SARS-CoV-2 Infections Among Health Care Workers.
Angel Y; Spitzer A; Henig O; Saiag E; Sprecher E; Padova H; Ben-Ami R
JAMA; 2021 Jun; 325(24):2457-2465. PubMed ID: 33956048
[TBL] [Abstract][Full Text] [Related]
9. Association of BNT162b2 mRNA and mRNA-1273 Vaccines With COVID-19 Infection and Hospitalization Among Patients With Cirrhosis.
John BV; Deng Y; Scheinberg A; Mahmud N; Taddei TH; Kaplan D; Labrada M; Baracco G; Dahman B
JAMA Intern Med; 2021 Oct; 181(10):1306-1314. PubMed ID: 34254978
[TBL] [Abstract][Full Text] [Related]
10. Association Between BNT162b2 Vaccination and Incidence of SARS-CoV-2 Infection in Pregnant Women.
Goldshtein I; Nevo D; Steinberg DM; Rotem RS; Gorfine M; Chodick G; Segal Y
JAMA; 2021 Aug; 326(8):728-735. PubMed ID: 34251417
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness of COVID-19 Vaccines in Preventing Hospitalization Among Adults Aged ≥65 Years - COVID-NET, 13 States, February-April 2021.
Moline HL; Whitaker M; Deng L; Rhodes JC; Milucky J; Pham H; Patel K; Anglin O; Reingold A; Chai SJ; Alden NB; Kawasaki B; Meek J; Yousey-Hindes K; Anderson EJ; Farley MM; Ryan PA; Kim S; Nunez VT; Como-Sabetti K; Lynfield R; Sosin DM; McMullen C; Muse A; Barney G; Bennett NM; Bushey S; Shiltz J; Sutton M; Abdullah N; Talbot HK; Schaffner W; Chatelain R; Ortega J; Murthy BP; Zell E; Schrag SJ; Taylor C; Shang N; Verani JR; Havers FP
MMWR Morb Mortal Wkly Rep; 2021 Aug; 70(32):1088-1093. PubMed ID: 34383730
[TBL] [Abstract][Full Text] [Related]
12. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
Akova M; Unal S
Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
[TBL] [Abstract][Full Text] [Related]
13. Evaluating risk factors associated with COVID-19 infections among vaccinated people early in the U.S. vaccination campaign: an observational study of five states, January-March 2021.
Sadigh KS; Kugeler KJ; Bressler S; Massay SC; Schmoll E; Milroy L; Cavanaugh AM; Sierocki A; ; Fischer M; Nolen LD
BMC Infect Dis; 2022 Sep; 22(1):718. PubMed ID: 36050630
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study.
Lopez Bernal J; Andrews N; Gower C; Robertson C; Stowe J; Tessier E; Simmons R; Cottrell S; Roberts R; O'Doherty M; Brown K; Cameron C; Stockton D; McMenamin J; Ramsay M
BMJ; 2021 May; 373():n1088. PubMed ID: 33985964
[TBL] [Abstract][Full Text] [Related]
15. Tolerability of COVID-19 Infection and Messenger RNA Vaccination Among Patients With a History of Kawasaki Disease.
Beckley M; Olson AK; Portman MA
JAMA Netw Open; 2022 Aug; 5(8):e2226236. PubMed ID: 35960521
[TBL] [Abstract][Full Text] [Related]
16. FDA-authorized mRNA COVID-19 vaccines are effective per real-world evidence synthesized across a multi-state health system.
Pawlowski C; Lenehan P; Puranik A; Agarwal V; Venkatakrishnan AJ; Niesen MJM; O'Horo JC; Virk A; Swift MD; Badley AD; Halamka J; Soundararajan V
Med; 2021 Aug; 2(8):979-992.e8. PubMed ID: 34223401
[TBL] [Abstract][Full Text] [Related]
17. COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines.
Meo SA; Bukhari IA; Akram J; Meo AS; Klonoff DC
Eur Rev Med Pharmacol Sci; 2021 Feb; 25(3):1663-1669. PubMed ID: 33629336
[TBL] [Abstract][Full Text] [Related]
18. Assessing real-world vaccine effectiveness against severe forms of SARS-CoV-2 infection: an observational study from routine surveillance data in Switzerland.
Anderegg N; Althaus CL; Colin S; Hauser A; Laube A; Mäusezahl M; Wagner M; Zaffora B; Riou J
Swiss Med Wkly; 2022 Apr; 152():w30163. PubMed ID: 35752951
[TBL] [Abstract][Full Text] [Related]
19. COVID-19 vaccine effectiveness among the staff of the Bologna Health Trust, Italy, December 2020-April 2021.
Giansante C; Stivanello E; Perlangeli V; Ferretti F; Marzaroli P; Musti MA; Pizzi L; Resi D; Saraceni S; Pandolfi P
Acta Biomed; 2021 Sep; 92(4):e2021270. PubMed ID: 34487060
[TBL] [Abstract][Full Text] [Related]
20. Age and product dependent vaccine effectiveness against SARS-CoV-2 infection and hospitalisation among adults in Norway: a national cohort study, July-November 2021.
Starrfelt J; Danielsen AS; Buanes EA; Juvet LK; Lyngstad TM; Rø GØI; Veneti L; Watle SV; Meijerink H
BMC Med; 2022 Sep; 20(1):278. PubMed ID: 36050718
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
